The DOI matches its Crossref record.
The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy
Abstract
Summary: Rodent models of chronic epilepsy with spontaneous recurrent seizures likely represent the closest parallel to the human condition. Such models may be best suited for therapy discovery for pharmacoresistant epilepsy and for antiepileptogenic or disease‐modifying therapeutics. However, the use of such rodent models for therapy discovery creates problems with regard to maintaining effective drug levels throughout a prolonged testing period. This is particularly due to the fact that rodents such as rats and mice eliminate most drugs much more rapidly than humans. Thus, knowledge about elimination rate of a test drug in a laboratory species is essential for development of a treatment paradigm that allows maintaining adequate drug levels in the system over the period of treatment. Currently, the most popular models of epilepsy with spontaneous seizures are poststatus epilepticus models of temporal lobe epilepsy in rats. Such models are both used for studies on antiepileptogenesis and drug resistance. For validation of these models, current antiepileptic drugs (AEDs) have to be used. In this article, the elimination rates of these AEDs and their effective plasma levels in rats are reviewed as a guide for developing treatment protocols for chronic drug testing. The advantages and disadvantages of several technologies for drug delivery are discussed, and some examples for calculation of adequate treatment protocols are given. As shown in this review, because of the rapid elimination of most AEDs in rats, it is no trivial task to maintain effective steady‐state AED levels in the plasma throughout the day over multiple days to ensure that there will be adequate levels in the system for the purpose of the experiment. However, the use of an adequate dosing regimen that is based on elimination rate is an absolute prerequisite when using rat models for discovery of new antiepileptogenic therapies or therapies for pharmacoresistant epilepsy, because otherwise such models may lead to erroneous conclusions about drug efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observed short half-life in the present study occurs for several reasons. First, the dose used in our clearance study is small (<0.1 mg/kg). By comparison, many other pharmacokinetic studies in rats use doses that are several orders of magnitude greater, as much as 200 mg/kg [Löscher, 2007].”
From Clearance kinetics of the VGF-derived neuropeptide TLQP-21 (2018) · cites this paper as Löscher, 2007
In the citing paper
“Typically, the half-lives for peptides are significantly shorter in rodents compared to humans [Löscher, 2007].”
From Clearance kinetics of the VGF-derived neuropeptide TLQP-21 (2018) · cites this paper as Löscher, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 90
- Adusumalli VE, 1991, Felbamate pharmacokinetics in the rat, rabbit, and dog, Drug Metabolism and Disposal: the Biological Fate of Chemicals, 19, 1116
- Ali A, 2006, Effect of semi‐chronic carbamazepine treatment on spontaneous seizures in rats with kainate‐induced epilepsy: a drug‐in‐food method of AED administration, Epilepsia, 47, 297
- Ashley JJ, 1972, Inhibition of diphenylhydantoin elimination by its major metabolite, Res Commun Chem Pathol Pharmacol, 4, 297
- Atlas SA, 1980, Genetic differences in phenytoin pharmacokinetics: in vivo clearance and in vitro metabolism among inbred strains of mice, Dev Pharmacol Ther, 1, 281, 10.1159/000455547 · doi:10.1159/000455547
- Bartoszyk GD, 1986, New anticonvulsant drugs, 147
- 10.1080/0049825042000196749 · DOI
- Bertram E, 2005, Testing drugs for antiepileptic efficacy in a rat model of chronic limbic epilepsy, Epilepsia, 46, 281
- 10.1111/j.1528-1167.2007.00980.x · DOI
- Bhargava HN, 1995, Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies, NIDA Res Monogr, 147, 53
- 10.1212/WNL.32.10.1122 · DOI
- 10.1016/j.neuropharm.2006.05.021 · DOI
- 10.1111/j.0013-9580.2004.16904.x · DOI
- Browne TR, 2002, Antiepileptic drugs, 565
- 10.1111/j.2042-7158.1980.tb12861.x · DOI
- 10.1007/BF03190614 · DOI
- 10.1046/j.1472-8206.2002.00096.x · doi:10.1046/j.1472-8206.2002.00096.x
- 10.1016/j.ejphar.2003.09.065 · DOI
- 10.1177/106002809302700215 · DOI
- Dickinson RG, 1979, Disposition of valproic acid in the rat: dose‐dependent metabolism, distribution, enterohepatic recirculation and choleretic effect, J Pharmacol Exp Ther, 211, 583
- 10.1016/S0920-1211(98)00104-1 · DOI
- 10.1007/978-3-642-60072-2_23 · doi:10.1007/978-3-642-60072-2_23
- 10.1016/0006-8993(94)90631-9 · DOI
- Farghali H, 1976, Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects, Arch Int Pharmacodyn Ther, 220, 125
- File SE, 1993, Benzodiazepine withdrawal: behavioural pharmacology and neurochemical changes, Biochem Soc Symp, 59, 97
- 10.1016/S1461-5347(99)00162-5 · DOI
- Gerber N, 1971, Study of dose‐dependent metabolism of 5,5‐diphenyl‐hydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro, J Pharmacol Exp Ther, 178, 567
- 10.1097/00008877-199603000-00009 · DOI
- 10.1046/j.1528-1157.2002.18101.x · DOI · Paper page
- Grabenstatter HL, 2006, Effects of intraperitoneal and oral carbamazepine on spontaneous seizures in rats with kainate‐induced epilepsy, Epilepsia, 47, 306
- 10.1111/j.0013-9580.2005.13404.x · DOI
- Gram L, 1986, New anticonvulsant drugs, 229
- 10.1016/S0028-3908(00)00183-0 · doi:10.1016/s0028-3908(00)00183-0
- 10.1023/A:1015953715346 · doi:10.1023/a:1015953715346
- Holck HGO, 1937, Studies upon the sex‐difference in rats in tolerance to certain barbiturates and to nicotine, J Pharmacol Exp Ther, 60, 323
- 10.1016/0028-3908(89)90139-1 · DOI
- 10.1111/j.1528-1157.1995.tb01613.x · DOI
- 10.1007/BF00497022 · doi:10.1007/bf00497022
- 10.1080/009841096161960 · DOI
- 10.3109/00498258209038950 · doi:10.3109/00498258209038950
- Kato R, 1992, Sex‐specific cytochrome P450 as a cause of sex‐ and species‐related differences in drug toxicity, Toxicology Letters, 64
- 10.1002/ana.410050512 · doi:10.1002/ana.410050512
- 10.1016/0920-1211(94)00070-D · DOI
- Levy RH, 2002, Antiepileptic drugs
- 10.1002/hep.1840100417 · DOI · Paper page
- Löscher W, 1978, Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse, J Pharmacol Exp Ther, 204, 255
- 10.1016/0091-3057(86)90449-1 · doi:10.1016/0091-3057(86)90449-1
- 10.2165/00023210-200216100-00003 · DOI · Paper page
- Löscher W, 1978, Pharmacokinetics of sodium valproate in dog and mouse, Arzneimittel-Forsch, 28, 782
- 10.1016/0014-2999(89)90294-X · DOI
- 10.1111/j.1528-1157.1995.tb01637.x · DOI
- 10.1038/nrn1728 · DOI · Paper page
- 10.1016/0014-2999(90)90309-T · DOI
- 10.1016/0920-1211(88)90054-X · DOI · Paper page
- 10.1016/S0920-1211(02)00063-3 · DOI
- 10.1016/j.eplepsyres.2006.03.014 · DOI
- 10.1111/j.1528-1167.2006.00607.x · DOI · Paper page
- 10.1016/0014-4886(85)90026-3 · DOI
- 10.1016/0920-1211(90)90013-L · doi:10.1016/0920-1211(90)90013-l
- 10.1016/0920-1211(91)90075-Q · DOI · Paper page
- 10.1016/0920-1211(91)90062-K · DOI · Paper page
- 10.1111/j.1528-1157.1995.tb00993.x · doi:10.1111/j.1528-1157.1995.tb00993.x
- Löscher W, 1998, Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy, J Pharmacol Exp Ther, 284, 474, 10.1016/S0022-3565(24)37251-9 · DOI · Paper page
- Mattson RH, 2002, Antiepileptic drugs, 72
- 10.1615/CritRevNeurobiol.v12.i4.40 · DOI · Paper page
- 10.1111/j.1528-1157.1986.tb03572.x · DOI · Paper page
- 10.1258/002367792780809011 · doi:10.1258/002367792780809011
- 10.1016/0041-008X(85)90081-X · DOI · Paper page
- 10.1002/bdd.2510030405 · doi:10.1002/bdd.2510030405
- 10.1002/bdd.2510040209 · DOI
- 10.1515/CCLM.2004.245 · DOI · Paper page
- Patsalos PN, 2002, Antiepileptic Drugs, 428
- Perkins L, 1999, Encyclopedia of controlled drug delivery, version 2, 900
- 10.1016/0024-3205(88)90150-6 · DOI · Paper page
- 10.1016/S0920-1211(98)00074-6 · DOI
- Radulovic LL, 1995, Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys, Drug Metab Dispos, 23, 441
- 10.1016/0014-2999(92)90624-D · DOI
- Rundfeldt C, 1993, Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala‐kindled rats, J Pharmacol Exp Ther, 266, 216
- 10.1016/S0920-1211(02)00069-4 · DOI
- 10.1016/0163-7258(88)90007-1 · DOI
- 10.1111/j.0013-9580.2003.32803.x · DOI · Paper page
- 10.1016/S0893-133X(00)00243-8 · DOI
- Taylor CP, 1986, New anticonvulsant drugs, 277
- 10.2165/00003495-200161080-00002 · DOI
- 10.1007/978-3-642-69518-6_19 · doi:10.1007/978-3-642-69518-6_19
- 10.1046/j.1365-2796.2000.00758.x · doi:10.1046/j.1365-2796.2000.00758.x
- Van Der Klejin, 1971, Pharmacokinetics of diazepam in dogs, mice and humans, Acta Pharmacol Toxicol (Copenh) 29 Suppl, 3, 109, 10.1111/j.1600-0773.1971.tb03291.x · doi:10.1111/j.1600-0773.1971.tb03291.x
- 10.1111/j.1528-1167.2006.00496.x · DOI · Paper page
- 10.1038/sj.bjp.0703337 · DOI
- 10.1016/j.seizure.2004.01.007 · DOI
- Welty D, 1997, Pharmacokinetics (PK) and pharmacodynamics (PD) of CI‐1009 (pregabalin) ans gabapentin in rats with maximal electroshock, Epilepsia, 38, 35
Cited by
Clearance kinetics of the VGF-derived neuropeptide TLQP-21
Guo, Z., Sahu, B. S., He, R., Finan, B., Cero, C., Verardi, R., Razzoli, M., Veglia, G., Di Marchi, R. D., Miles, J. M., et al. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.06.003 · Cited by 21
Metadata
- Authors
- Löscher, W.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2007-04-18
- Volume
- 48
- Issue
- 7
- Pages
- 1245-1258
- ISSN
- 0013-9580
- 1528-1167
- Cited by
- 113
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy. https://app.cochat.ai/papers/10.1111/j.1528-1167.2007.01093.x
- The paper
- Löscher, W. (2007). The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy. Epilepsia. https://doi.org/10.1111/j.1528-1167.2007.01093.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.